Fleury S.A. (FLRY3) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.050x

Based on the latest financial reports, Fleury S.A. (FLRY3) has a cash flow conversion efficiency ratio of 0.050x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$264.56 Million ≈ $51.91 Million USD) by net assets (R$5.28 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fleury S.A. net asset quality index to measure how much of total assets are equity-financed.

Fleury S.A. - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Fleury S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check FLRY3 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Fleury S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fleury S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
JetBlue Airways Corp
NASDAQ:JBLU
0.066x
Aerospace Industrial Development Corp
TW:2634
0.164x
Beijing Fuxing Xiaocheng Electronic Technology Co Ltd
SHE:300139
0.006x
Kansai Nerolac Paints Limited
NSE:KANSAINER
0.031x
OFG Bancorp
NYSE:OFG
0.028x
Shanghai Weaver Network Co Ltd
SHG:603039
0.046x
Henan Lingrui Pharmaceutical Co Ltd
SHG:600285
0.038x
Shenzhen Forms Syntron Information Co Ltd
SHE:300468
0.070x

Annual Cash Flow Conversion Efficiency for Fleury S.A. (2006–2025)

The table below shows the annual cash flow conversion efficiency of Fleury S.A. from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Fleury S.A. (FLRY3) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 R$5.10 Billion
≈ $999.98 Million
R$1.57 Billion
≈ $308.32 Million
0.308x -14.16%
2024-12-31 R$5.37 Billion
≈ $1.05 Billion
R$1.93 Billion
≈ $378.80 Million
0.359x +27.54%
2023-12-31 R$5.11 Billion
≈ $1.00 Billion
R$1.44 Billion
≈ $282.42 Million
0.282x -22.94%
2022-12-31 R$2.70 Billion
≈ $530.00 Million
R$987.13 Million
≈ $193.69 Million
0.365x -33.47%
2021-12-31 R$1.85 Billion
≈ $363.88 Million
R$1.02 Billion
≈ $199.88 Million
0.549x +48.61%
2020-12-31 R$1.75 Billion
≈ $343.55 Million
R$647.14 Million
≈ $126.98 Million
0.370x -11.22%
2019-12-31 R$1.76 Billion
≈ $345.14 Million
R$732.32 Million
≈ $143.69 Million
0.416x +3.86%
2018-12-31 R$1.75 Billion
≈ $343.37 Million
R$701.49 Million
≈ $137.64 Million
0.401x +29.17%
2017-12-31 R$1.71 Billion
≈ $334.85 Million
R$529.61 Million
≈ $103.92 Million
0.310x -11.67%
2016-12-31 R$1.54 Billion
≈ $301.34 Million
R$539.57 Million
≈ $105.87 Million
0.351x +57.78%
2015-12-31 R$1.66 Billion
≈ $324.83 Million
R$368.63 Million
≈ $72.33 Million
0.223x +22.60%
2014-12-31 R$1.57 Billion
≈ $308.64 Million
R$285.71 Million
≈ $56.06 Million
0.182x +46.38%
2013-12-31 R$1.69 Billion
≈ $331.42 Million
R$209.59 Million
≈ $41.12 Million
0.124x +26.71%
2012-12-31 R$1.71 Billion
≈ $334.73 Million
R$167.05 Million
≈ $32.78 Million
0.098x +9.49%
2011-12-31 R$1.63 Billion
≈ $320.20 Million
R$145.96 Million
≈ $28.64 Million
0.089x -19.86%
2010-12-31 R$1.01 Billion
≈ $198.53 Million
R$112.92 Million
≈ $22.16 Million
0.112x +289.62%
2009-12-31 R$838.97 Million
≈ $164.62 Million
R$24.03 Million
≈ $4.72 Million
0.029x -93.99%
2008-12-31 R$151.84 Million
≈ $29.79 Million
R$72.40 Million
≈ $14.21 Million
0.477x -39.20%
2007-12-31 R$101.35 Million
≈ $19.89 Million
R$79.48 Million
≈ $15.60 Million
0.784x +16.44%
2006-12-31 R$105.91 Million
≈ $20.78 Million
R$71.33 Million
≈ $14.00 Million
0.673x --

About Fleury S.A.

SA:FLRY3 Brazil Diagnostics & Research
Market Cap
$1.84 Billion
R$9.39 Billion BRL
Market Cap Rank
#6444 Global
#70 in Brazil
Share Price
R$17.27
Change (1 day)
-0.52%
52-Week Range
R$13.90 - R$17.95
All Time High
R$26.18
About

Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and cli… Read more